Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 25, 2020 06:30 ET | Source: Morphic Therapeutic

Morphic Announces that AbbVie Exercises License Option to αvβ6 Integrin Inhibitor Program, Including MORF-720, for Fibrotic Diseases

AbbVie to pay Morphic license fee of $20 million, with future potential milestones and royalties AbbVie to lead further development and commercialization WALTHAM, Mass., Aug. 25, 2020 (GLOBE...
August 10, 2020 07:00 ET | Source: Morphic Therapeutic

Morphic Announces Corporate Highlights and Second Quarter 2020 Financial Results

Company’s first IND accepted by FDA for MORF-057 in IBDPhase 1 study expected to begin in third-quarter 2020Positive data presented at DDW 2020 further support MORF-057 preclinical profile WALTHAM,...
June 29, 2020 07:30 ET | Source: Morphic Therapeutic

Morphic Therapeutic Presents Positive Preclinical Data Supporting Development of MORF-057 in Inflammatory Bowel Disease at Digestive Disease Week 2020

Receptor occupancy, potency and selectivity data further build MORF-057 preclinical profile as an oral small molecule treatment candidate for IBD IND filing on track for mid-year and phase 1 clinical...
June 18, 2020 08:00 ET | Source: Morphic Therapeutic

Morphic to Present at the BMO 2020 Prescriptions for Success Healthcare Virtual Conference

WALTHAM, Mass., June 18, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment...
May 27, 2020 08:00 ET | Source: Morphic Therapeutic

Morphic to Present at the Jefferies Virtual Healthcare Conference

WALTHAM, Mass., May 27, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment...
May 06, 2020 16:05 ET | Source: Morphic Therapeutic

Morphic Announces Corporate Highlights and First Quarter 2020 Financial Results

Data presented at ECCO Congress support MORF-057 in IBD; IND on track for mid-year Recent executive appointments of Peter Linde, M.D., as CMO and Marc Schegerin, M.D., as CFO and COO ...
April 29, 2020 16:15 ET | Source: Morphic Therapeutic

Morphic Therapeutic to Present at the BofA Securities 2020 Health Care Conference

WALTHAM, Mass., April 29, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment...
April 07, 2020 08:00 ET | Source: Morphic Therapeutic

Morphic Announces Appointment of Marc Schegerin, M.D., as Chief Financial Officer and Chief Operating Officer

WALTHAM, Mass., April 07, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
March 17, 2020 08:00 ET | Source: Morphic Therapeutic

Morphic Announces Appointment of Peter G. Linde, M.D., as Chief Medical Officer

WALTHAM, Mass., March 17, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
February 28, 2020 08:00 ET | Source: Morphic Therapeutic

Morphic Therapeutic to Present at the 40th Annual Cowen Health Care Conference

WALTHAM, Mass., Feb. 28, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment...